Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax

03 July 2014 Law360 News

Law360

Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed a citizen petition made by the research firm Clinipace Worldwide asking the U.S. Food and Drug Administration to issue a finding that Merck & Co. did not discontinue the osteoporosis drug Fosamax for health and safety reasons. Rosen was quoted saying, “There have been relatively few instances where the FDA has withdrawn the reference listed drug for reasons related to safety or effectiveness.”

Related Services

Insights

Review of Recent Whistleblower Developments
30 July 2021
Legal News: Whistleblower Developments
$4.24M Now the Average Cost Per Data Breach!
30 July 2021
Internet, IT & e-Discovery Blog
Podcast Episode 56: All Things Summer Associate Recruiting
30 July 2021
Foley Career Perspectives
Foley Podcast to Live Panel Discussion
29 July 2021
Foley Career Perspectives
30th Annual Law of Product Distribution & Franchise Seminar
29 September | 7 & 20 October 2021
Milwaukee | Chicago | Dallas
7th National Telehealth Summit
4-5 October 2021
Miami Beach, FL
AHLA Fraud & Compliance Forum
21-22 September 2021
Baltimore, MD
2nd Clinical Trial Agreements Forum
16-17 September 2021
Online Livestream